This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
| 26.03.2013 |
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) |
|---|---|
| 11.12.2012 |
Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves |
| 10.12.2012 |
Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin |
| 05.12.2012 |
New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session |
| 08.11.2012 |
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF |
Preventing AF related strokes is vital. Protecting your brain protects your world.